Fig. 7
SEPT2-K74cr may be a potential biomarker for predicting prognosis and HCC recurrence in patients (A) Scores indicate crotonylation of SEPT2-K74cr (K74-Cr) in representative tumor tissues as determined by immunohistochemistry (IHC) staining. Scores were calculated on the basis of the staining intensity and percentage of stained cells. B Patients with high K74-Cr levels had lower overall survival than those with low K74-Cr levels. C Patients with high K74-Cr levels had a higher recurrence rate than those with low K74-Cr levels. D Representative images of tissues with low and high stage pathology as determined by hemoxylin and eosin (H, E) and IHC staining. E Quantitative comparison of the IHC score in the tissues with low and high stage pathology. The data are presented as the means ± SD. *p < 0.05. F Quantitative comparison of the K74-Cr IHC scores in metastasis tissue and primary HCCs in Tissue microarray (HLivH060CD03) (G) Images showing bone metastasis tissue and the corresponding primary HCC tumor after H&E and IHC staining. H Graphic model showing the effect of SEPT2-K74 crotonylation in HCC. K74 crotonylation was negatively regulated by SIRT2, and K74 decrotonylation decreased P85α stability and PI3K pathway activity, which inhibited HCC metastasis. SEPT2-K74 crotonylation can serve as an independent predictor of low patient survival and HCC recurrence